These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39380740)

  • 1. Regional diversity in drug-induced lung diseases among the USA, European Union, and Japan.
    Sato J; Sadachi R; Koyama T; Katsuya Y; Okada M; Yamamoto N
    Front Med (Lausanne); 2024; 11():1390083. PubMed ID: 39380740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
    Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
    Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system.
    Lin W; Xu J; Liao Y; Lin X; Yang J; Zhuang W
    Int J Clin Pharm; 2024 Jun; 46(3):614-622. PubMed ID: 38100054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
    Godfrey H; Jedlowski P; Thiede R
    Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
    Tang L; Sun C; Liu W; Wu H; Ding C
    Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
    [No Abstract]   [Full Text] [Related]  

  • 7. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
    Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
    Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
    Ebinama U; Sheshadri A; Anand K; Swaminathan I
    J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vonoprazan-associated
    Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M
    Ther Adv Drug Saf; 2024; 15():20420986241260211. PubMed ID: 39091466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wei Q; Wu X
    Front Pharmacol; 2022; 13():986357. PubMed ID: 36408225
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS).
    Mao K; Chen P; Sun H; Zhong S; Zheng H; Xu L
    Front Pharmacol; 2024; 15():1425617. PubMed ID: 39228525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
    Jiang A; Wei C; Zhu W; Wu F; Wu B
    Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
    Wang H; Yang H; Zhou X; Zhang X
    Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
    Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
    Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
    Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
    BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.
    Cui C; Deng L; Wang W; Ren X; Wang Y; Cui W
    Front Oncol; 2022; 12():941079. PubMed ID: 36059699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
    Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
    Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.